RLAY · Insider Trading
Relay Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by RLAY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-08 | Thomas Catinazzo | Chief Financial Officer | Sell | −17,717 | −$329.32K |
| 2026-10-08 | Sanjiv Patel | President and CEO | Sell | −48,199 | −$872.40K |
| 2026-09-09 | Donald A Bergstrom | President, R&D | Sell | −8,530 | −$161.81K |
| 2026-09-09 | Thomas Catinazzo | Chief Financial Officer | Sell | −17,717 | −$335.56K |
| 2026-09-09 | Sanjiv Patel | President and CEO | Sell | −48,199 | −$912.89K |
| 2026-08-28 | Peter Rahmer | See remarks | Sell | −4,508 | −$90.30K |
| 2026-08-28 | SVF Pauling (Cayman) Ltd | 10%+ Owner | Sell | −18,000,000 | −$349.20M |
| 2026-08-18 | Thomas Catinazzo | Chief Financial Officer | Sell | −17,717 | −$349.73K |
| 2026-08-18 | Sanjiv Patel | President and CEO | Sell | −48,199 | −$979.89K |
| 2026-07-30 | Donald A Bergstrom | President, R&D | Sell | −2,237 | −$41.63K |
| 2026-07-30 | Peter Rahmer | See remarks | Sell | −748 | −$13.92K |
| 2026-07-30 | Thomas Catinazzo | Chief Financial Officer | Sell | −1,459 | −$27.15K |
| 2026-07-08 | Sanjiv Patel | President and CEO | MIXED | −45,143 | −$922.50K |
| 2026-07-08 | Thomas Catinazzo | Chief Financial Officer | Sell | −17,717 | −$331.13K |
| 2026-07-08 | Donald A Bergstrom | President, R&D | Sell | −8,660 | −$162.03K |
| 2026-07-02 | Peter Rahmer | See remarks | MIXED | −46,944 | −$933.26K |
| 2026-06-24 | Donald A Bergstrom | President, R&D | MIXED | — | −$1.20M |
| 2026-06-24 | Thomas Catinazzo | Chief Financial Officer | MIXED | −17,717 | −$2.34M |
| 2026-06-10 | Claire Mazumdar | Director | A | +32,947 deriv. | — |
| 2026-06-10 | Douglas S Ingram | Director | A | +32,947 deriv. | — |
| 2026-06-10 | Lonnel Coats | Director | A | +32,947 deriv. | — |
| 2026-06-10 | Linda A Hill | Director | A | +32,947 deriv. | — |
| 2026-06-10 | Habib J Dable | Director | A | +32,947 deriv. | — |
| 2026-06-10 | Alexis Borisy | Director | A | +32,947 deriv. | — |
| 2026-06-10 | Mark Murcko | Director | A | +32,947 deriv. | — |
| 2026-05-14 | Thomas Catinazzo | Chief Financial Officer | Sell | −17,717 | −$227.84K |
| 2026-04-09 | Thomas Catinazzo | Chief Financial Officer | MIXED | −17,717 | −$248.10K |
| 2026-03-11 | Thomas Catinazzo | Chief Financial Officer | Sell | −17,717 | −$178.23K |
| 2026-01-29 | Peter Rahmer | See remarks | MIXED | −12,044 | −$97.50K |
| 2026-01-29 | Donald A Bergstrom | President, R&D | Sell | −21,581 | −$166.68K |
| 2026-01-29 | Thomas Catinazzo | Chief Financial Officer | Sell | −15,515 | −$119.63K |
| 2026-01-15 | Donald A Bergstrom | President, R&D | A | +575,000 deriv. | — |
| 2026-01-15 | Sanjiv Patel | President and CEO | A | +1,450,000 deriv. | — |
| 2026-01-15 | Peter Rahmer | See remarks | A | +475,000 deriv. | — |
| 2026-01-15 | Thomas Catinazzo | Chief Financial Officer | A | +400,000 deriv. | — |
| 2026-01-07 | Sanjiv Patel | President and CEO | MIXED | −42,174 | −$334.60K |
| 2025-11-06 | Lonnel Coats | Director | A | +207,931 deriv. | — |
| 2025-11-06 | Habib J Dable | Director | A | +207,931 deriv. | — |
| 2025-11-04 | Sanjiv Patel | President and CEO | Sell | −62,073 | −$434.51K |
| 2025-10-30 | Thomas Catinazzo | Chief Financial Officer | Sell | −21,664 | −$157.93K |
| 2025-10-30 | Donald A Bergstrom | President, R&D | Sell | −30,897 | −$225.24K |
| 2025-10-30 | Peter Rahmer | See remarks | Sell | −40,529 | −$299.95K |
| 2025-07-30 | Thomas Catinazzo | Chief Financial Officer | Sell | −20,081 | −$74.00K |
| 2025-07-30 | Brian Adams | Chief Legal Officer | Sell | −19,913 | −$73.38K |
| 2025-07-30 | Peter Rahmer | See remarks | Sell | −17,083 | −$62.95K |
| 2025-07-30 | Donald A Bergstrom | President, R&D | Sell | −30,770 | −$113.48K |
| 2025-07-10 | Sanjiv Patel | President and CEO | Sell | −61,379 | −$219.12K |
| 2025-07-01 | Peter Rahmer | See remarks | A | +5,000 | +$14.70K |
| 2025-07-01 | Sanjiv Patel | President and CEO | A | +5,000 | +$14.70K |
| 2025-06-11 | Claire Mazumdar | Director | A | +421,241 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| SVF Pauling (Cayman) Ltd | 10%+ Owner | 21,904,963 | $398.45M |
| Mark Murcko | Director | 996,952 | $18.13M |
| Sanjiv Patel | President and CEO | 670,849 | $12.20M |
| Donald A Bergstrom | President, R&D | 399,130 | $7.26M |
| Brian Adams | Chief Legal Officer | 389,748 | $7.09M |
| Alexis Borisy | Director | 234,175 | $4.26M |
| Peter Rahmer | See remarks | 223,657 | $4.07M |
| Thomas Catinazzo | Chief Financial Officer | 105,340 | $1.92M |
| Jami Rubin | Director | 67,242 | $1.22M |
| Douglas S Ingram | Director | 25,000 | $454.75K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RLAY quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.